Quest Diagnostics Incorporated (DGX)

NYSE: DGX · IEX Real-Time Price · USD
140.55
-0.02 (-0.01%)
Aug 12, 2022 4:03 PM EDT - Market closed
-0.01%
Market Cap 16.39B
Revenue (ttm) 10.58B
Net Income (ttm) 1.48B
Shares Out 116.61M
EPS (ttm) 12.05
PE Ratio 11.66
Forward PE 15.08
Dividend $2.56 (1.82%)
Ex-Dividend Date Jul 5, 2022
Volume 640,159
Open 140.60
Previous Close 140.57
Day's Range 139.45 - 141.39
52-Week Range 125.33 - 174.16
Beta 0.99
Analysts Buy
Price Target 147.75 (+5.1%)
Earnings Date Jul 21, 2022

About DGX

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent ... [Read more...]

Industry Health Care Providers & Services
IPO Date Dec 17, 1996
CEO Stephen Rusckowski
Employees 50,000
Stock Exchange NYSE
Ticker Symbol DGX
Full Company Profile

Financial Performance

In 2021, DGX's revenue was $10.79 billion, an increase of 14.32% compared to the previous year's $9.44 billion. Earnings were $2.00 billion, an increase of 39.41%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is 147.75, which is an increase of 5.12% from the latest price.

Price Target
$147.75
(5.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Paige Announces Partnership with Sonora Quest Laboratories to Accelerate Precision Diagnostics for Patients Across Ar...

NEW YORK--(BUSINESS WIRE)--Paige, a global leader in clinical AI applications for pathology, today announced it will partner with Sonora Quest Laboratories, the local market leader in clinical diagnosti...

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J. , Aug. 10, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quar...

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

10 defensive stocks that can also provide you with growth and dividends over the long term

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

These 3 Companies Are Taking on Monkeypox

A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.

Other symbols: LHSIGA

QUEST DIAGNOSTICS BRIDGING ACCESS TO BETTER HEALTH FOR HISPANICS THROUGH ES TU PODER INITIATIVE

IRVING, Texas , Aug. 4, 2022 /PRNewswire/ -- Better healthcare among America's large and growing Hispanic community is receiving an important, new level of support from Quest Diagnostics, the world's le...

Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Fifth Consecutive Year

SECAUCUS, N.J. , July 27, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2022 Disability Equality...

High Rates of Chronic Hepatitis B and Tuberculosis Co-Infection Observed in Nationally Representative Quest Diagnosti...

Analysis of nearly 23 million lab tests finds only 1 in 3 patients with latent tuberculosis were also tested for chronic hepatitis B, despite similar risk factors in patients Findings heighten caution a...

Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View

Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.

Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics profit drops but testing firm raises 2022 view

Quest Diagnostics Inc. DGX, -1.33% said Thursday its second-quarter net income fell to $234 million, or $1.96 a share from $631 million, or $4.96 a share in the year-ago quarter. Adjusted profit in the ...

Quest Diagnostics Reports Second Quarter 2022 Financial Results; Raises Guidance for Full Year 2022

Second quarter revenues of $2.45 billion, down 3.8% from 2021 Second quarter reported diluted earnings per share ("EPS") of $1.96, down 60.5% from 2021; and adjusted diluted EPS of $2.36, down 25.8% fro...

Rite Aid and Quest Diagnostics Expand Access to COVID-19 PCR Testing Nationwide

PHILADELPHIA & SECAUCUS, N.J.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) today announced it is collaborating with Quest Diagnostics (NYSE: DGX) to provide access to quality, COVID-19 molecular testing (poly...

Other symbols: RAD

5 Dividend-Paying Stocks to Buy Ahead of Earnings Next Week

Five dividend-paying companies will report second-quarter 2022 earnings results next week. These are: HAL, FNB, DGX, SLB and NEP.

Other symbols: FNBHALNEPSLB

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?

Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.

Quest Diagnostics to launch monkeypox test in August

Quest Diagnostics Inc. DGX, -1.38% said Wednesday that it developed a monkeypox test that it plans to launch in August. The PCR test, which is administered by a physician, can detect monkeypox and also ...

Quest Diagnostics Launches Monkeypox Virus Testing

Company to be able to perform approximately 30,000 tests a week by the end of July, supplementing public health response Physicians can order the novel Quest Diagnostics lab test beginning today and the...

Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal

Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.

Quest Diagnostics Releases 2021 Corporate Responsibility Report

SECAUCUS, N.J. , July 11, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today released its 2021 Corporate Responsibility Report.

Quest Diagnostics Partners with CDC to Extend $0 Out-of-pocket COVID-19 Diagnostic Testing to Underserved Communities

Qualified uninsured individuals now have access to the company's COVID-19 molecular diagnostic testing at approximately 1,200 Quest Diagnostics patient service centers SECAUCUS, N.J. , July 7, 2022 /PRN...

Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes

Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.

Quest Diagnostics to Release Second Quarter 2022 Financial Results on July 21, 2022

SECAUCUS, N.J. , June 24, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2...

7 Undervalued Large-Cap Stocks to Buy Before Wall Street Catches On

Even if the market has not yet reached the point of bottoming-out, these seven undervalued large-cap stocks are worth a look. The post 7 Undervalued Large-Cap Stocks to Buy Before Wall Street Catches On...

Other symbols: APABTICPBFOXLUMNTAP

Is Quest Diagnostics (DGX) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...